New Dako Omnis RTU antibodies
Introduction of 13 new high quality FLEX RTU antibodies for Dako Omnis.
PD-L1 IHC 28-8 pharmDx training
Learn how to evaluate PD-L1 expression in both non-squamous NSCLC and melanoma patients for OPDIVO® (nivolumab).
Leading the way
in PD-L1 testing
Introducing the first and only FDA-approved test to assess patients with NSCLC for KEYTRUDA® (pembrolizumab).
Review of Breast Cancer Diagnosis
In collaboration with leading experts, Agilent publishes a new comprehensive review on breast cancer diagnostic testing.
Results you can trust
The first and only FDA-approved PD-L1 test for use in both non-squamous NSCLC and melanoma for OPDIVO® (nivolumab).
See our solutions within pathology, next generation sequencing and molecular cancer research.
New Product Catalog Available
The 2016 Pathology Product Catalog is now available.
Events and Congresses
Meet us at congresses and events around the world.